Quipt Home Medical (NASDAQ:QIPT) & Accuray (NASDAQ:ARAY) Head-To-Head Analysis

Quipt Home Medical (NASDAQ:QIPT) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Quipt Home Medical and Accuray’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quipt Home Medical	-1.71%	-3.89%	-1.76%
Accuray	-4.99%	-44.46%	-4.54%

Insider & Institutional Ownership

42.9% of Quipt Home Medical shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 4.2% of Quipt Home Medical shares are held by company insiders. Comparatively, 3.8% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Quipt Home Medical has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Quipt Home Medical and Accuray, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quipt Home Medical	1	0	3	2	3.00
Accuray	0	0	3	0	3.00

Quipt Home Medical currently has a consensus price target of $7.25, suggesting a potential upside of 91.29%. Accuray has a consensus price target of $8.25, suggesting a potential upside of 329.69%. Given Accuray’s higher possible upside, analysts clearly believe Accuray is more favorable than Quipt Home Medical.

Valuation & Earnings

This table compares Quipt Home Medical and Accuray’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quipt Home Medical	$221.74 million	0.73	-$2.78 million	($0.10)	-37.90
Accuray	$447.61 million	0.43	-$9.28 million	($0.22)	-8.73

Quipt Home Medical has higher earnings, but lower revenue than Accuray. Quipt Home Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Summary

Quipt Home Medical beats Accuray on 8 of the 13 factors compared between the two stocks.

About Quipt Home Medical

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.